CMS Takes A Back Seat to No One When it Comes to Drug Safety
This article was originally published in RPM Report
Executive Summary
Amgen, J&J and a host of supporters urged CMS to wait until FDA completes its safety review of EPO before acting to limit coverage. CMS is having none of it.
You may also be interested in...
Straight Talk About Cancer Drug Coverage
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
Straight Talk About Cancer Drug Coverage
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
Avoiding Another EPO: Amgen's Nplate Has FDA Restrictions, But May Escape Medicare Controls
The Centers for Medicare & Medicaid Services is considering national coverage restrictions for Amgen's newly approved Nplate (romiplostim). CMS is ostensibly concerned about a lack of long-term data. Based on Medicare's experience with previous Amgen products, CMS may also be worried about long-term costs. But Amgen says CMS there is no need for Amgen to get involved: FDA has the situation well in-hand with a REMS risk management program.